A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 591 participants.

Also called NCT04809220

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 591 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04809220
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04809220. Randomized; double masking; primary purpose treatment. Start 2021-04-13 (actual); primary completion 2022-10-01 (actual). Results posted on 2023-09-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
Acronym
AWARD-JPN
Condition
Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Condition
Glucose Metabolism Disorders
Condition
Metabolic Disease
Condition
Endocrine System Diseases
Condition
Hypoglycemic Agents
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Oral antihyperglycemics
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04809220
Content hash
f507ad19cc5c206d4e0bd7bc56eae4dbc35bb27776578d39481e67ecd14ba654